Kawasaki Heavy Industries, Ltd. hereby notifies that the Company has recorded a loss on valuation of shares of subsidiaries and associates and a provision for loss on guarantees under extraordinary losses as follows in the unconsolidated results for the fiscal year ended March 31, 2024 (April 1, 2023 to March 31, 2024).

1. Details of extraordinary losses
Regarding the shares of Medicaroid Corporation held by Kawasaki, as its real value decreased, Kawasaki has recorded a loss on valuation of shares of subsidiaries and associates of ¥12,955 million and a provision for loss on guarantees of ¥5,231 million under extraordinary losses in the unconsolidated results for the fiscal year ended March 31, 2024.
This was due to anticipated development costs in the medical robot business of Medicaroid in its transition from the investment and development phase to the growth phase. As Kawasaki considers the medical robot business of Medicaroid will enter a growth phase from now on, Kawasaki will continue to invest in this business as well as our own medical robot business.

2. Impact on the consolidated financial results
The losses above mentioned have no impact on the consolidated financial results for the fiscal year ended March 31, 2024 because they are eliminated in the consolidated financial statements.

-End of document-